| abstract |
The proposed alkylated piperazine compounds of the formula I, including their stereoisomers, tautomers and pharmaceutically acceptable salts, are used to inhibit Btk kinase and to treat immune disorders such as inflammation mediated by Btk kinase. Disclosed are methods of using compounds of Formula I for in vitro, in situ and in vivo diagnosis and for the treatment of such disorders in mammalian cells or associated pathological conditions. |